Why We Exist

The mission of the End Kids Cancer Foundation, a leading pediatric cancer research charity, is to provide financial support for research and clinical trials that will cure neuroblastoma (NB), with an emphasis on non-toxic treatments. Our narrow focus on neuroblastoma is designed to increase the success of finding a cure. While the focus is narrow, the benefits derived will be broad. Studies have shown that advancements in the treatment of pediatric neuroblastoma, including those conducted by End Kids Cancer-funded researchers, can lead to breakthroughs against many common deadly cancers affecting adults. These include lung cancer, breast cancer, kidney cancer, brain cancer, liver cancer, prostate cancer and skin cancer.As a secondary mission, End Kids Cancer works to disseminate the vital information we acquire  while we pursue our primary mission of funding the cure. That’s why we produced Steps to Hope, a free booklet that shows parents and caregivers, in just 40 pages, how to navigate the pediatric cancer research landscape and secure the cutting-edge treatments that could save their children’s lives. 

Where We're Headed

A child anywhere in the United States who is diagnosed with neuroblastoma is very likely to be treated by therapies developed by the doctors on our Medical Review Board. The research we have directly funded is already bearing fruit. Our support of the early phases of some of the most promising non-toxic treatments has been followed by FDA and NCI funding and support.

Those who study neuroblastoma and other pediatric cancers are members of an elite research community. It was a team of pediatric oncologists who, despite being grossly underfunded, achieved the first significant cure rate (80%) for acute lymphoblastic leukemia (ALL) in 1968.

Pediatric cancer researchers have been responsible for introducing some of the most significant treatment protocols in the fight against all cancers, and they have done so on a shoestring budget. They were the first to develop a multi-disciplinary treatment approach, which utilizes the optimum orchestration of chemotherapy, radiation, immunotherapy and surgery.

Pediatric oncologists were the first to use multiple drugs and collaborate with hospitals all over the world to discover the best treatment plans. Yet prevention is the most effective way to fight disease. This is the absolute domain of pediatricians and pediatric researchers. Many cancers take decades to evolve, and many begin their development in the early, formative years of an adult.

As we learn more about pediatric cancer, doctors are able to intervene sooner. The best example of this is the new vaccine recently introduced that is administered to teenage girls to prevent cervical cancer. This research will benefit people. As a result, there are no other areas in cancer research where your donations will have a greater significance.


Medical Advisors

Dr. Robert Seeger

Robert Seeger, M.D., Ph.D., is Professor of Pediatrics at the Keck School of Medicine, Director of Cancer Research Program of the Saban Research Institute, and Division Head for Basic and Translational Research of the Center for Cancer and Blood Diseases at Children’s Hospital Los Angeles. Dr. Seeger is considered one of the leaders in the fight against neuroblastoma. He has been involved in every major advancement in treating neuroblastoma, including the pivotal 1984 discovery of the first-ever amplification of an oncogene (cancer-causing gene) for any cancer, MYCN, and the demonstration that MYCN could be used to predict outcomes.


Dr. Malcolm K. Brenner

Malcolm K. Brenner, M.D., Ph.D., is the director of the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital and The Methodist Hospital. He is also director of the Shell Center for Gene Therapy at BCM and a professor in the Departments of Pediatrics and Medicine, Section of Hematology-Oncology. Before coming to Baylor, he was one of the pioneers in the field of gene therapy at St. Jude Children’s Cancer Research Center in Memphis. Dr. Brenner is a co-editor of the journal Molecular Therapy, a member of the American Society of Gene Therapy and a principal investigator or co-investigator on five NIH grants. He is the author or co-author of more than 200 professional articles in his field. He was the first to cure a child with
neuroblastoma using T cells.


Dr. Paul Sondel

Paul Sondel, M.D., Ph.D., is the Reed and Carolee Walker Professor in Pediatric Oncology at the University of Wisconsin–Madison. Dr. Sondel has been a leader in scientific policy through multiple national committee roles, including the National Institutes of Health, the American Cancer Society, the Children’s Oncology Group (COG), and the National Cancer Institute, where he was a member of the Board of Scientific Counselors, and St. Jude’s Children’s Research Hospital, where he was the Chair of their Scientific Advisory Committee and is now chair of their cancer center’s external advisory board. Due to his extensive background in genetics and tumor immunology, Dr. Sondel led his team to dramatically change the treatment for neuroblastoma, and, in turn, the survival rate for children with this high-risk disease.


Dr. Andras Heczey

Andras Heczey, M.D., is a physician-scientist and full-time faculty member in the Department of Pediatrics of Baylor College of Medicine, Section of Pediatric Hematology and Oncology. He is a member of the multidisciplinary solid tumor team and the Center for Cell and Gene Therapy (CAGT). His research focuses on developing novel treatments for children with solid tumors by redirecting the immune system to attack cancer cells. Dr. Heczey has studied and published the first adoptive immunotherapy approach utilizing Natural Killer T cells genetically modified to attack neuroblastoma. He is working on moving this approach from bench to bedside in the form of a Phase 1/2a clinical trial.

Dr. Modak Baby Girl Cropped.png

Dr. Shakeel Modak

Shakeel Modak, M.D., Ph.D., joins us from the Department of Pediatric Hematology-Oncology, Immunotherapy, Neuroblastoma at Memorial Sloan-Kettering Cancer Center, New York, New York. Dr. Modak is a pediatric oncologist who specializes in the treatment of children and young adults with neuroblastoma and other solid tumors, such as desmoplastic small round cell tumors. With his colleagues, he translates laboratory research into new immunologic therapies that can target these tumors.
He and his team are evaluating radiolabeled monoclonal antibody treatments in combination with cell-based therapies that may enhance their effectiveness. His team’s research has defined the standard of care
used to treat neuroblastoma today.





Dr. Stein, is the former President of the American Academy of Pediatrics. He is a founding member of the Section of Critical Care, the Council of Sections Management Committee and the Committee on Membership of the AAP. As a member of the technical advisors of the Pan American Health Organization for the Integrated Management of Childhood Illnesses (IMCI), he has been extremely active in advocacy for children in impoverished environments at the global level. He is a leader in the area of chronically-ill children as survivors of intensive care. More than 1300 residents have rotated through the unit he has directed for the past 35 years. Residents under Dr. Stein's Progressive Care Unitlearn the intricacies of caring for children with technological dependency and the complexities of chronic care, re-imbursement and social and educational re-incorporation of this ever-increasing group of patients. 


Non-Medical Advisors

Frank Kalman, Executive Director and Founder

Mr. Kalman is Executive Director and Founder of the End Kids Cancer Foundation. He founded the organization in response to the tremendous challenge he witnessed in his daughter Calli’s battle with neuroblastoma and in meeting the many dedicated medical researchers working to cure the disease. Frank received his undergraduate degree in Marketing/Business from California Polytechnic State University and worked in the marketing department of American Honda for several years.


Christopher Kennedy Lawford

Mr. Lawford was an early supporter of the foundation as an advisor. He has spent much of his life in Washington and Hollywood, navigating these two worlds as an actor, writer, lawyer, activist and public speaker. Mr. Lawford is currently working with the United Nations, the Canadian Center on Substance Abuse, and the World Health Organization in efforts to raise awareness globally about addiction steps and hepatitis. His uncle, the late Senator Edward M. Kennedy, authored the 21st Century Cancer Access to Life-Saving Early Detection, Research and Treatment (ALERT) Act, a comprehensive bill to address the broad issues the nation faces in combatting cancer. 


Scott Wall, Esq.

Mr. Wall is Chairman of the Estate Planning, Trusts and Probate Practice Group and is a member of the Business and Real Estate Transactions Practice Group. He is certified by the State Bar of California as a specialist in estate planning, trust and probate law. Before starting his law practice, he was a Certified Public Accountant. He received his J.D. degree
from the University of California–Hastings College of Law in 1986.


Sue Andersen

Sue Andersen is Vice President and CFO for Catholic Healthcare West Hospitals on the Central Coast of California, including French Hospital Medical Center, Marian Medical Center, and Arroyo Grande
Community Hospital.


Guy Rathbun

Mr. Rathbun is a radio host at KCBX Public Radio, Public Radio Exchange. Guy began his career in broadcasting as a field reporter in 1975. From 1983 to 1991 and again between 1999 and 2011, he taught Broadcasting, Audio Production and Broadcast Writing at Cuesta College.


Bill Hagelstein

Mr. Hagelstein is President and Chief Executive Officer of the independent advertising agency RPA. His career as a renowned advertising and marketing executive includes work for some of the most prominent brands in the world, including Ford, Honda, Mazda, Nissan, Yokohama Tire Corporation, Blue Cross/Blue Shield, Men’s Health, and DirecTV. He is also active in a range of civic and professional organizations that include the World Presidents’ Organization, the American Advertising Federation (AAF), the Performing Arts and Music Center of Los Angeles County,
and the AD Council.


Tom Peyton

Mr. Peyton is Vice President of Marketing for American Honda and earned his MBA at the University of Southern California. Mr. Peyton joined Honda in 2001 as the senior manager of marketing operations. Later, he served as senior manager of Honda Advertising, directing Honda brand advertising and marketing, which included creative strategy, media, digital, social and event marketing.


Patrick Kerans

Patrick Kerans has over 20 years of experience leading marketing teams for companies in Silicon Valley and as a consultant at Arthur D. Little, A.T. Kearney, and his own firm, Omnimarc. He is a cancer survivor and huge believer in the power of lay people to partner with medical professionals.


William Yoast, Honorary Chairman

Mr. Yoast is the honorary chair of the board of directors for the End Kids' Cancer Foundation. A legendary high school football coach with a career spanning more than 40 years, Yoast is best known for being portrayed in the 2000 film Remember the Titans.